

COMIRNATY CLINICAL TRIAL

| | Comirnaty | Placebo | Absolute/Relative Effectiveness |
|---|-----------------|-----------------|------------------------------------|
| Group size | 22,000 | 22,000 | |
| Adverse Events | 6,600 30.00% | 3,080 14.00% | -114% -16.00% |
| Severe Adverse Events | 264 1.20% | 154 0.70% | -71% -0.50% |
| Cases | 77 0.35% | 850 3.86% | 91% 3.51% |
| Cases (with prior infection) | 2 0.01% | 7 0.03% | 71% 0.02% |
| Severe Cases | 1 0.00% | 30 0.14% | 97% 0.13% |
| Deaths | 15 0.07% | 14 0.06% | -7% 0.00% |
| Severe Adverse Events / Severe Cases | 13x | | |
| Severe Adverse Events / Cases (with prior infection) | 46x | | |

Source: <https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1.full.pdf>